Dose escalation with intensity-modulated radiation therapy (IMRT) for carcinoma of the prostate has augmented the need for accurate prostate localization prior to dose delivery. Daily planar kilovoltage (kV) imaging is a low-dose image-guidance technique that is prevalent among radiation oncologists. However, clinical outcomes evaluating the benefit of daily kV imaging are lacking. The purpose of this study was to report our clinical experience, including prostate motion and gastrointestinal (GI) and genitourinary (GU) toxicities, using this modality. A retrospective analysis of 100 patients treated consecutively between December 2005 and March 2008 with definitive external beam IMRT for T1c-T4 disease were included in this analysis. Prescription doses ranged from 74-78 Gy (median, 76) in 2 Gy fractions and were delivered following daily prostate localization using on-board kV imaging (OBI) to localize gold seed fiducial markers within the prostate. Acute and late toxicities were graded as per the NCI CTCAEv3.0. The median follow-up was 22 months.
Introduction
Intensity modulated radiation therapy (IMRT) has become increasingly popular for localized prostate cancer radiotherapy because it allows for highly conformal dose distributions that optimize dose to target structures while limiting normal tissue involvement (1) (2) (3) (4) . This is an important concept given mounting evidence that dose to critical organs, such as bladder and rectum, is predictive of toxicity (5).
Due to the high conformality associated with IMRT, target localization is critical for precise dose delivery. Multiple techniques have been developed to this end, including electronic portal imaging device (EPID) (6) (7) , ultrasound-based systems (8-10), electromagnetic transponder systems (11) (12) (13) (14) , megavoltage tomotherapy computed tomography (CT) (15, 16) , and on-board CT (17, 18) . Daily use of on-board imaging (OBI) with Trilogy (Varian Medical Systems, Palo Alto, CA) and orthogonal kilovoltage (kV) images is another technique for this purpose. Because these technologies have been implemented fairly recently, there are little data documenting treatment outcomes and toxicity profiles in patients treated with image guided intensity modulated radiotherapy (IG-IMRT) compared to those treated with IMRT and conventional setup technique.
We have employed IG-IMRT at our institution since 2005. In this study, we report acute and early-late gastrointestinal (GI) and genitourinary (GU) toxicity, initial biochemical response, set-up error, and target motion in a group of prostate cancer patients receiving IG-IMRT with daily OBI to match gold-seed fiducial markers implanted within the prostate.
Material and Methods
Prostate cancer patients that were consecutively treated between December 2005 and January 2008 with definitive external beam IG-IMRT at University of California, San Diego were included in this Institutional Review Board (IRB)-approved retrospective study.
RT Technique
Prior to treatment planning, three gold markers were implanted in the prostate using trans-rectal ultrasound guidance. All patients were subsequently planned for IMRT to the prostate and seminal vesicles and underwent simulation with computed tomography (CT) in the supine position with a Vac-Loc (Med-Tec, Orange City, IA) cushion for immobilization. Patients were instructed to keep their bladder full (by drinking 350 mL of water) and rectum empty (by means of an enema) during the planning session and at the time of treatment to ensure reproducibility of daily positioning. At initial simulation, axial CT images of the pelvis were obtained with 2.5 mm slice thickness. The initial clinical target volume (CTV) included the prostate and proximal seminal vesicles, and the cone down CTV included the prostate. The planning target volume (PTV) was generated with an 8-10 mm margin in all directions except posteriorly where the margin was reduced to 5 mm. The superior margin was also tightened to exclude small bowel from the high-dose RT zone. An IMRT plan was generated using seven-field technique with Eclipse planning software (Varian Medical Systems). The total prescribed doses ranged between 74-78 Gy (median, 76) in 2 Gy fractions. Fifty-six to 60 Gy was delivered to the initial PTV, which included the prostate and first third of the seminal vesicles, and the remaining dose prescribed to the prostate. Twenty-two selected high risk patients received pelvic nodal IMRT to doses of 46-50 Gy, followed by a boost to bring the prostate and proximal seminal vesicles to full dose. All patients received one fraction per day and five fractions per week.
Image Guided Radiation Therapy (IGRT) Technique
The treatment isocenter was set up at the time of CT simulation and based on the location of CTV. The skin triangulation points of the isocenter were tattooed as guided by the laser coordinate system of the CT scanner (GE Healthcare, Waukesha, WI). All patients had orthogonal digital reconstructed radiographs (DRR) created from the treatment planning CT. Gold seed fiducial markers were contoured and projected onto the DRRs to be used for comparison with the fiducials as seen on the kV images obtained using the OBI system. Orthogonal (anterior-posterior and lateral) kV images were acquired daily to localize the prostate based on seed location (Figure 1 ). Shifts were recorded in the anterior-posterior (AP), left-right (LR), and superior-inferior (SI) directions on a daily basis.
Androgen Deprivation Therapy
Patients received androgen deprivation therapy at the discretion of the treating physician, with indications including intermediate to high-risk cancer and cytoreduction. Intermediate risk patients received 3 months of neoadjuvant ADT that was continued during their radiation treatment. Higher risk patients received 3 months of neoadjuvant ADT that was continued during their radiation treatment and for up to 2 years after treatment.
Measurement of Toxicity
Patients were evaluated weekly during treatment, one month after the completion of radiotherapy, and every 3-6 months thereafter. Patient charts both before and after radiotherapy, as well as all electronically available records, were reviewed for toxicity assessment. In addition, patients not seen within the last 3 months were contacted by phone and interviewed for specific symptoms. Acute toxicity included side effects occurring during the course of radiation and up to three months following the completion of treatment. Late toxicity included any symptoms occurring more than three months after completion of radiotherapy. Symptoms present before radiotherapy were not included in this data unless those symptoms became more severe during the surveillance period. Symptom severity was graded on a scale of 1 to 5, according to the Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0) (19).
Biochemical Response
To assess early biochemical response rates, prostate-specific antigen (PSA) levels were measured at the beginning of treatment, one to three months after completion of treatment, and every six months thereafter. Biochemical failure after external beam radiotherapy was defined according to the Phoenix definition of PSA elevation of 2 ng/mL above the nadir (20).
Measurement of Setup Error and Prostate Motion
Patients were set up based on skin marks applied at the time of simulation, and shifts were then made to align fiducial markers. Daily setup shifts were measured in three different axes (SI, AP, and LR). Shift data for all 100 patients was not available, because it was not recorded for our initial patients. Shift data was reported for all patients for which it was available. The additional patients were included in the sample in order to improve analysis of toxicity.
Prostate motion is defined as the change in position of the prostate in relation to pelvic bony anatomy. In order to measure this, we used Offline Review software (Varian Medical Systems) to overlay the pelvic bony anatomy from AP and lateral OBI kV images for each fraction with the corresponding DRR. Once bony anatomy was aligned, the movement of the prostate in relation to the pelvic skeleton was measured as the difference in prostate position on portal image versus DRR. We measured the magnitude of this difference in three axes (SI, AP, and LR) for each fraction. Setup error was defined as the inaccuracy in patient alignment using skin tattoos, which can be measured as daily changes in the position of the pelvic bony anatomy with tattoo alignment. Since total error is a combination of both setup error and prostate motion, we calculated setup error as total error minus prostate motion in each of the three axes for all fractions.
Total error was defined as the change in position of the fiducial markers on the orthogonal kV on-board images compared to the original DRR orthogonal images from simulation CT. Total error is the sum of prostate motion and setup error.
The relationships between rectal volume and SI, AP, LR and total shift were analyzed using a linear regression model. Values were log transformed to eliminate skew.
Results

Patient Characteristics
One hundred patients were treated consecutively between December 2005 and March 2008 (Table I) .
Prostate Motion, Set-up Error, Total Error
Prostate displacement and set-up error were measured in 1,968 orthogonal image pairs from 58 patients, and total error was measured in 2,910 orthogonal image pairs from 88 patients (Table II) .
Acute Toxicity
No patients experienced grade 3 or higher acute toxicity. Eight patients (8%) experienced no acute side effects. For GU toxicity, seventy-nine patients (79%) developed acute side effects, with grade 1 events occurring in 40 patients (40%) and grade 2 events in 39 patients (39%). The most common acute GU radiation effects were frequency and dysuria (Figure 2) . For GI toxicity, fifty-three patients (53%) reported acute GI side effects, with grade 1 toxicity in 42 patients (42%) and grade 2 effects in 11 patients (11%). The most common GI toxicity was diarrhea (Figure 2 ). (18%) with grade 1 symptoms and 15 (16%) with grade 2 symptoms. For GI toxicity, nine patients (9%) had late GI toxicity, 7 (7%) with grade 1 symptoms and 2 (2%) with grade 2 symptoms (Figure 3 ).
Biochemical Response, Local Failure, and Survival
Pre-and post-treatment PSA levels were available for 97 of the 100 patients included in this study. All patients except one had a decreased PSA at the end of treatment compared to the beginning. At least one patient had PSA levels that continued to decrease 16 months after treatment. By last follow-up, only one patient experienced biochemical failure according to the Phoenix definition. That patient had a prostate biopsy which confirmed local recurrence. Overall survival was 99%; one patient died of pneumonia. No patients died of prostatecancer related causes.
Discussion
IMRT with and without high-dose escalation is being increasingly used for the management of prostate cancer (21). Moreover, image-guidance techniques are also being rapidly integrated into treatment delivery alongside IMRT in an effort to account for the potentially serious consequences
Late Toxicity
Ninety-four patients had long-term follow-up ranging from 7 to 36 months, with a median follow-up of 22 months. No patients experienced grade three or higher late toxicity. For GU toxicity, thirty-two patients (34%) had late events, 17 
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is relatively small when compared to the total dose delivered during treatment.
We documented organ motion and setup error using our OBI system. Although average displacements were low, the range of motion was substantial, with 9.1% and 12.9% of prostate displacements being ≥ 5 mm in the AP and SI directions, respectively Rectal volumes at simulation were not found to be significantly associated with the magnitude of SI, AP, LR or total shifts. The prostate was more mobile in the AP and SI axes than in the lateral direction, which is consistent with previously reported data (6) and likely due to interfractional changes in rectal and bladder volumes. Set up according to tattoos would have clearly been suboptimal, since a substantial proportion (for example, 28% in the AP direction) of shifts were ≥ 5 mm. These data highlight the importance of using IG-IMRT to prevent toxicity due to rectal or bladder expansion, which can push normal tissues into the treatment field and the target out.
While multiple retrospective studies have recorded acute and late toxicity profiles in prostate cancer patients treated definitively with IMRT, there is little data regarding outcomes in patients treated with IG-IMRT using our technique. Overall, the majority of patients treated with IMRT alone experience grade 1 to 2 acute toxicity, with GI effects in 26-87% of patients, and GU effects in 64-87% of patients (2-3, 23-25). Additionally, it is not uncommon to see grade 3 or higher GU effects, with up to 7% in one study (2).
We are aware of three recent retrospective studies assessing toxicity outcomes in prostate cancer patients treated with IG-IMRT using intra-prostatic fiducial markers for position verification. One small study involved 25 high-risk patients and reported grade 1 acute GI and GU toxicity in 53% and 93% of patients, respectively, grade 2 toxicity in 7% and 7% of patients respectively, and no patients with grade 3 or higher acute toxicity (26). Unfortunately, this study did not evaluate late toxicity. A second small study reported acute of interfractional target motion. However, despite growing popularity, clinical outcomes associated with the use of daily kV imaging for prostate cancer IG-IMRT are sparse. The primary goal of this study was to present our clinical data on prostate motion and GI/GU toxicities in a large cohort of patients treated using this form of image-guidance. Overall, our results demonstrate significant prostate motion, as well as a favorable toxicity profile, supporting the role of IG-IMRT in the management of this disease.
Multiple image-guidance devices have been developed to correct for setup error and organ motion (6-18). As described above, we use an on-board imager to capture orthogonal kV x-ray images and align gold seed fiducial markers implanted within the prostate. The obvious advantage of using on-board imaging is that shifts made directly on overlapping simulation and on-board images at the time of treatment can be translated directly to the patient in real-time using couchshift software. One disadvantage to daily kV x-ray images is the possibility of a substantial cumulative dose of radiation over the course of treatment. The dose to pelvic organs and skin from daily CBCT is estimated to range from 3.8-6.2 cGy (22 
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Grade I Grade II Figure 3 : Percentage of patients with late toxicity. Furthermore, this is a retrospective study, and as such, toxicities may have been missed due to lack of documentation. We however have tried to overcome this limitation by evaluating all available electronic records and phoning patients for additional follow-up.
In conclusion, IMRT for localized prostate cancer requires precise and accurate target localization at the time of treatment delivery. IG-IMRT may improve both treatment efficacy and side effect profiles by correcting for organ motion and patient setup discrepancy. In this study, a substantial amount of prostate motion, particularly in the AP and SI directions, was observed. However, our patients treated with dose-escalated IMRT with image-guidance using daily planar kV imaging had a favorable toxicity profile, as well as excellent initial PSA control outcomes. Even more importantly, none of our patients developed high-grade toxicity. We therefore recommend daily IG-IMRT with kV-kV image matching to align gold seed fiducial markers implanted within the prostate to enhance treatment precision for prostate cancer patients undergoing definitive external beam radiotherapy. Ultimately, longer follow-up is necessary to better define the true benefits and risks of this technique. and late toxicity in 39 prostate cancer patients treated with 80 Gy IG-IMRT. Using CTCAE v.3, this group reported acute and late grade 3 GU toxicity in 8% and 3% of patients, respectively, and no patients with grade 3 or higher acute or late GI toxicity (27) . A third recent study measured toxicity in a larger group of patients after a mean follow-up of 47 months (28) . Moderate to severe toxicity was more common in this study; 3% of patients had Radiation Therapy Oncology Group (RTOG)/European Organization for Research and Treatment of Cancer (EORTC) grade 3 acute GU toxicity, one patient experienced RTOG/EORTC grade 4 late GU toxicity and one patient experienced RTOG/EORTC grade 4 late rectal toxicity (Table III) .
In contrast to these prior studies, our series presents a larger cohort of patients in which no severe acute or late toxicity was reported. Overall, the side effect profile of our patients was generally favorable, demonstrating similar rates of lowgrade side effects but with no grade 3 or higher events at any time during treatment or follow-up. Furthermore, one study assessing long-term outcomes in patients treated with IMRT to a dose of 81 Gy documented several grade 3 rectal toxicity events, and 15% of patients experienced grade 2 or higher GU toxicity (1). Our patients had similar rates of low-grade toxicity, but none experienced the grade 3 or higher effects.
Multiple toxicity scoring criteria have been developed to accurately report and assess adverse events associated with the management of cancer patients. Commonly used systems include the RTOG/EORTC scale (30), NCI CTCAE (19), and Late Effects Normal Tissue Task Force (LENT)-Subjective, Objective, Management, Analytic (SOMA) scales (31), as well as other in-house systems that have not been validated prospectively. The RTOG/EORTC scale grades toxicity in 16 organ systems and was widely employed, however it does not provide broad enough criteria for encompassing all side effect profiles. The SOMA-LENT scale is a comprehensive system that provides both objective and subjective measures of toxicity, but can be cumbersome to implement into clinical practice owing to its length (32). The NCI CTCAE scale has the advantage of being a comprehensive, multimodality toxicity scale that employs both subjective and objective data in the assessment of cancer patients and has been widely adopted by oncologists (33).
Although promising, our study has several limitations. While 100 patients is a larger cohort of patients than prior studies have observed, it is still a relatively small sample size. Furthermore, since on-board imaging is a still relatively novel technology, our median follow-up was 22 months. Late toxicity symptoms peak during the third year following treatment (34), and therefore longer follow-up is needed to describe the complete late toxicity profiles. However, the majority of toxicities are generally seen in the first two years.
